(Reuters) -GSK said on Friday that adding its cancer drug Jemperli to both standard-of-care chemotherapy and Zejula as a maintenance therapy improved survival in patients with advanced ovarian cancer without the disease getting worse in a late-stage trial, meeting its main goal. However, GSK said that the trial evaluating Zejula and Jemperli in first line advanced ovarian cancer failed to meet